How appendix cancer treatment works, from first diagnosis to surgery, and what to ask along the way.
Appendix cancer is rare. Most doctors will see only a handful of cases, or none, in an entire career. That’s why getting to a specialist matters more for this disease than for almost any other cancer. This page walks you through how appendix cancer is diagnosed, what appendix cancer treatment options exist, and what questions to bring to your appointments.
This information is patient education, not medical advice. Always discuss your specific situation with a qualified medical team, ideally one that includes a surgical oncologist experienced in peritoneal surface malignancies.
How Appendix Cancer Is Diagnosed
Most appendix cancers are found by accident.
A patient comes in with what looks like appendicitis. Surgery removes the appendix. Pathology, the lab examination of the tissue, finds cancer cells. That’s how the majority of appendix cancer diagnoses happen. The patient didn’t go to the doctor because of cancer. They went because of pain. The cancer was a surprise.
In other cases, imaging done for a separate reason (kidney stones, abdominal pain, a routine scan) shows something unexpected, a mass on the appendix, mucinous material in the abdomen, or signs that something has spread.
Pathology, The Most Important Step
Once an appendix is removed, the tissue goes to a pathologist. The pathology report is the single most important document in your appendix cancer journey. It tells you:
- What kind of appendix cancer it is (LAMN, HAMN, mucinous adenocarcinoma, goblet cell adenocarcinoma, neuroendocrine tumor, signet ring cell, undifferentiated, etc.)
- The grade, how aggressive the cancer cells look under a microscope
- Whether the tumor broke through the appendix wall, and whether cancer cells or mucin escaped into the abdomen
- The margins, whether all the cancer was removed during the appendectomy
Because appendix cancer is so rare, pathology reports are sometimes wrong or incomplete the first time around. The Godfrey 2025 consensus guidelines recommend that your pathology slides be reviewed by a pathologist experienced in appendiceal tumors. This is one of the most important steps you can take. A second pathology opinion at a specialty center can change your diagnosis, your stage, and your treatment plan.
Imaging, How Doctors Look for Spread
If the pathology shows cancer, imaging is the next step. The goal is to see whether cancer has spread beyond the appendix and how far.
CT scan (Computed Tomography) is the most common imaging test for appendix cancer. CT scans of the chest, abdomen, and pelvis show whether mucin or tumor has spread to other places in the abdomen, the lymph nodes, or distant organs. Contrast dye is usually used to make abnormalities easier to see.
MRI (Magnetic Resonance Imaging) uses a strong magnet (not radiation) to create detailed pictures of soft tissue. MRI is especially useful for evaluating peritoneal spread, cancer that has settled on the lining of the abdomen, because it shows soft-tissue detail that CT can sometimes miss.
PET scan uses a small amount of radioactive sugar to highlight areas where cells are very active (like cancer cells). PET scans are used selectively in appendix cancer, they work well for some types and less well for slow-growing mucinous tumors.
Diagnostic laparoscopy is a minimally invasive surgery where a surgeon makes small incisions and inserts a camera to look directly at the inside of the abdomen. This is sometimes done before major surgery to assess how much cancer is present and whether complete removal is realistic.
Tumor Markers, Blood Tests
Blood tests for tumor markers can support a diagnosis and help track how a cancer is responding to treatment. The three most relevant for appendix cancer are:
- CEA (carcinoembryonic antigen)
- CA 19-9
- CA-125
These markers are not used to diagnose appendix cancer on their own. Many people with appendix cancer have normal tumor marker levels, and many people without cancer have elevated levels for other reasons. But when markers are elevated at diagnosis, they can be useful for monitoring whether treatment is working over time.
Biopsy, When and Why
For appendix cancer, biopsies of the appendix itself are rarely possible before surgery. The diagnosis usually comes from examining the entire appendix after it’s removed. If cancer has spread to the abdominal lining or other tissue, those areas can be biopsied to confirm the type of cancer present.
What to Do After a Diagnosis
If you’ve just been diagnosed, here are the three most important steps in your appendix cancer treatment journey, in this order:
- Get your pathology reviewed by a specialty center. This is the single highest-impact step. The Peritoneal Surface Malignancies Consortium (the group behind the Godfrey 2025 guidelines) recommends pathology review by an expert pathologist for any appendiceal neoplasm diagnosis.
- Get a second opinion from an appendiceal cancer specialist, typically a surgical oncologist at a high-volume peritoneal surface malignancy program. Even if your local oncologist is excellent, appendix cancer is rare enough that specialist input changes treatment decisions in a meaningful number of cases.
- Don’t rush surgery. Outside of true emergencies, take the time to consult with specialists. Surgery done well the first time gives you the best chance of long-term survival. Surgery done at a center without appendiceal expertise can sometimes make subsequent treatment harder.
Appendix Cancer Treatment Options
Treatment for appendix cancer depends on several things:
- The specific type (LAMN, HAMN, mucinous adenocarcinoma, goblet cell adenocarcinoma, neuroendocrine tumor, signet ring cell, etc.)
- The grade and stage, how aggressive the cancer is and how far it has spread
- Whether mucin or tumor cells have spread to the abdominal lining (peritoneal disease)
- Your overall health and treatment goals
There is no single “appendix cancer treatment.” What works for one type of appendix cancer can be wrong for another. New to this? Start with our overview of appendix cancer, and keep our glossary of medical terms handy for unfamiliar words. This is the central reason specialist care matters.
The Godfrey 2025 consensus guidelines, developed by more than 138 physicians experienced in treating peritoneal surface malignancies, provide treatment recommendations based on each tumor type and stage. The summaries below reflect those guidelines.
Appendectomy
An appendectomy is surgery to remove the appendix. For many patients, this is how appendix cancer is first found, the appendix is removed for suspected appendicitis, and the cancer is discovered after the fact.
For some early-stage, low-grade tumors that are completely confined to the appendix and removed with clean margins, appendectomy alone may be enough treatment. This is most often the case with:
- Low-grade appendiceal mucinous neoplasms (LAMN) confined to the appendix with no rupture
- Small, well-differentiated neuroendocrine tumors (under 1 cm)
- Some early-stage adenocarcinomas with clean margins
The pathology report tells you whether more surgery is needed. If the appendix wall was breached, if there’s mucin in the abdomen, or if the tumor has higher-risk features, additional treatment is typically recommended.
Hemicolectomy (Right Colectomy)
A right hemicolectomy removes the appendix along with the right side of the colon and nearby lymph nodes. This is sometimes called a “completion colectomy” when it’s done after an initial appendectomy.
The Godfrey 2025 guidelines recommend right hemicolectomy for several scenarios, including:
- Larger neuroendocrine tumors (typically 2 cm or greater)
- Adenocarcinomas of the appendix
- Goblet cell adenocarcinomas
- Tumors with high-risk features (positive margins, lymphovascular invasion, certain grades)
The purpose is twofold: remove any remaining cancer in the area, and remove lymph nodes that can be examined for spread. Lymph node status helps determine whether additional treatment is needed.
Cytoreductive Surgery (CRS)
Cytoreductive surgery, sometimes called CRS or “the mother of all surgeries”, is an extensive operation to remove all visible cancer from the abdominal cavity. It’s used when appendix cancer has spread to the lining of the abdomen (the peritoneum).
This surgery can take anywhere from 6 to 14 hours. It typically involves removing affected sections of the peritoneum, omentum (a fatty apron-like tissue in the abdomen), and sometimes parts of other organs the cancer has reached, like portions of the small intestine, large intestine, spleen, gallbladder, or reproductive organs in women.
The goal of CRS is “complete cytoreduction”, removing every visible piece of cancer the surgeon can see. Achieving complete cytoreduction is one of the strongest predictors of long-term survival in appendix cancer.
CRS is a major operation with serious risks. It should only be performed at high-volume specialty centers with surgical teams experienced in peritoneal surface malignancies. The difference in outcomes between high-volume centers and low-volume centers is significant, this is one of the most important reasons to seek specialist care.
HIPEC, Hyperthermic Intraperitoneal Chemotherapy
HIPEC is almost always done at the end of cytoreductive surgery, while the patient is still under anesthesia.
After all visible cancer is removed, the surgeon circulates a heated chemotherapy solution (typically around 41-43°C / 106-109°F) inside the abdominal cavity for 60 to 90 minutes. The chemotherapy bathes the entire inside of the abdomen, targeting any microscopic cancer cells that might remain after surgery.
The combination is often called CRS/HIPEC or “the Sugarbaker procedure,” after Dr. Paul Sugarbaker who pioneered the approach.
For mucinous appendix cancer with peritoneal spread (including pseudomyxoma peritonei), CRS/HIPEC is the cornerstone of treatment in the Godfrey 2025 guidelines. For other types of appendix cancer with peritoneal spread, the role of HIPEC depends on the specific tumor biology, your specialist team will make recommendations based on your case.
Systemic Chemotherapy
Systemic chemotherapy, chemotherapy given through an IV that circulates throughout the body, has a more limited and specific role in appendix cancer than in many other cancers.
This is important to understand, because the role of chemotherapy in appendix cancer has changed significantly based on recent research:
- For low-grade mucinous appendiceal adenocarcinoma, recent randomized trial evidence has shown that systemic chemotherapy does not improve outcomes. The Godfrey 2025 guidelines recommend against routine systemic chemotherapy for low-grade mucinous disease.
- For high-grade mucinous adenocarcinoma, signet ring cell carcinoma, and goblet cell adenocarcinoma, systemic chemotherapy may be recommended depending on stage and risk factors. Common regimens include FOLFOX and FOLFIRI, combinations originally developed for colorectal cancer.
- For neuroendocrine tumors, different chemotherapy or targeted therapy approaches are used depending on tumor grade and spread.
This is one of the most important areas where specialist input matters. Many patients are offered chemotherapy regimens designed for colorectal cancer, which may or may not be the right treatment for their specific type of appendix cancer.
PIPAC, Pressurized Intraperitoneal Aerosol Chemotherapy
PIPAC is a newer approach that delivers chemotherapy as a pressurized mist directly into the abdominal cavity through laparoscopic ports. It’s typically used in cases where complete cytoreduction isn’t possible, to control disease, manage symptoms, or potentially convert someone to a candidate for full CRS/HIPEC.
PIPAC is available at a smaller number of specialty centers and is still being studied for appendix cancer specifically. It’s worth asking about if you’re seeing a specialist at a major peritoneal surface malignancy program.
Targeted Therapy and Immunotherapy
Targeted therapies are drugs that block specific molecules involved in cancer growth. For appendix cancer, the use of targeted therapy depends heavily on tumor genetics:
- KRAS, BRAF, and other mutations can sometimes be matched with specific drugs
- Microsatellite instability (MSI-high) tumors, though rare in appendix cancer, may respond to immunotherapy
- HER2-positive tumors may respond to HER2-targeted drugs
For most appendix cancers, genetic testing of the tumor is now considered standard of care to identify whether targeted therapy options exist. Ask your medical team whether your tumor has been tested for actionable mutations.
Clinical Trials
Because appendix cancer is rare, clinical trials are one of the most important paths to better treatments. Trials are available for various stages and types, including newer approaches like immunotherapy, novel targeted drugs, and refined HIPEC protocols.
Specialist centers can help match patients to relevant trials. The APPENDICURE Patient-Led Data Registry is another way patients contribute to research that may eventually expand treatment options for this rare disease.
Why Specialist Care Matters
For most cancers, treatment at your local hospital is fine. Appendix cancer treatment is different.
This disease is rare enough that the average oncologist will treat only a handful of cases in an entire career, sometimes none. Cytoreductive surgery with HIPEC is technically complex, and outcomes are measurably better at high-volume centers with surgical teams experienced in peritoneal surface malignancies. The difference isn’t small. It’s substantial.
The Godfrey 2025 consensus guidelines explicitly recommend that patients with appendix cancer, particularly those with peritoneal disease, be evaluated at experienced peritoneal surface malignancy programs.
What to Look For in a Specialist Center
When evaluating where to receive care, ask:
- Does the center have a dedicated peritoneal surface malignancy program?
- How many cytoreductive surgery / HIPEC procedures does the surgical team perform each year? (High-volume centers typically perform 50+ per year.)
- Is there a multidisciplinary team, surgical oncology, medical oncology, pathology, radiology, that meets regularly to discuss appendix cancer cases?
- Are clinical trials available at the center?
- Does the pathology department have experience reviewing appendiceal tumors specifically?
Be Prepared to Travel
Most patients with appendix cancer benefit from at least a consultation at a specialty center, even if some of their care happens locally. Many centers offer telemedicine consultations for initial reviews, which makes it easier to get specialist input without immediately traveling.
If you need to travel for surgery, that’s normal, and worth it. The decision of where to have CRS/HIPEC done is one of the most important medical decisions you will make.
What to Ask Your Doctor
Bring this list to every appointment. Write down the answers. Bring a second person if you can, someone to listen, take notes, and ask follow-up questions.
About Your Diagnosis
- What specific type of appendix cancer do I have?
- What is the grade and stage?
- Has my pathology been reviewed by a pathologist experienced in appendix cancer?
- Has the tumor been tested for genetic mutations?
- Has cancer spread beyond the appendix? Where?
About Treatment
- What treatment do you recommend, and why?
- What other treatment options exist for my specific type and stage?
- What are the Godfrey 2025 consensus recommendations for my situation?
- How experienced are you and this center with appendix cancer specifically?
- How many CRS/HIPEC procedures does your team perform each year?
- Are there clinical trials I should consider?
About Second Opinions
- Where would you recommend I go for a second opinion?
- Can you send my records and pathology slides to another center?
- Are there appendix cancer specialists you would refer me to?
A good doctor will not be offended by these questions. The Godfrey 2025 guidelines themselves emphasize the importance of multidisciplinary review and specialist input. If a provider discourages second opinions or downplays the value of specialist care, that itself is meaningful information.
Frequently Asked Questions
The NCCN (National Comprehensive Cancer Network) released its first appendix cancer guidelines in 2025, with version 2.2026 published in April 2026. NCCN guidelines are well-known in oncology and widely used for many cancer types.
For appendix cancer specifically, APPENDICURE uses the Godfrey 2025 consensus guidelines (published in the journal Cancer) as our primary content framework. There are several reasons:
- Broader expert consensus. The Godfrey 2025 guidelines were developed through a formal Delphi consensus process involving more than 138 physicians experienced in treating peritoneal surface malignancies, with greater than 90% agreement on key recommendations.
- Patient-aligned approach. The Godfrey 2025 guidelines reflect the recommendations of the Peritoneal Surface Malignancies Consortium, the physicians who actually perform high-volume appendix cancer care.
- Stronger evidence base in key areas. For some recommendations (like the limited role of systemic chemotherapy in low-grade mucinous disease), the Godfrey 2025 guidelines align with the strongest available randomized trial evidence.
Both sets of guidelines exist, and your medical team may reference either or both. We encourage patients to discuss treatment recommendations with their specialists and ask which guidelines are informing those recommendations.
Pseudomyxoma peritonei, usually shortened to PMP, is a clinical syndrome, not a type of cancer. It describes the buildup of mucinous material in the abdominal cavity, which usually originates from a ruptured low-grade or high-grade mucinous tumor of the appendix.
PMP can be slow-growing or aggressive depending on the underlying tumor type. Treatment typically involves cytoreductive surgery and HIPEC at a specialty center.
No. The appendix and colon are part of the same general region of the digestive tract, but appendix cancer behaves very differently from colon cancer. Some treatment approaches overlap (certain chemotherapy regimens, for example), but appendix cancer has its own pathology, biology, and treatment guidelines.
Patients are sometimes told they have “colon cancer” early in their diagnosis because that’s the closest analogy a non-specialist can offer. If your pathology actually shows appendix cancer, you should be treated by someone who understands appendix cancer specifically.
It depends entirely on the type. Low-grade mucinous tumors can grow slowly for years. High-grade adenocarcinomas, signet ring cell carcinomas, and some goblet cell tumors can be aggressive. Neuroendocrine tumors range from indolent to fast-growing depending on grade. This is one of the most important reasons to know your exact pathology, the prognosis and urgency vary widely.
Many patients with appendix cancer, especially those with early-stage or low-grade disease, and those who receive expert treatment for peritoneal disease, go on to live long, healthy lives. “Cure” is a complicated word in any cancer, but the long-term outcomes for many appendix cancer patients are considerably better than the average cancer patient assumes. Specialist care meaningfully changes outcomes.
Get the Support You Need
Facing appendix cancer is hard. Facing it without the right information, the right specialists, and the right community is harder.
APPENDICURE is here to help you navigate appendix cancer treatment. Our private community of 1,200+ patients and caregivers shares experience and support every day. Our public education is built on the strongest available evidence and reviewed by leading appendiceal cancer researchers.
Find an Appendix Cancer Specialist Join Our Community Join the Patient-Led Data Registry
Sources & References
This page is based on the Godfrey 2025 consensus guidelines for appendiceal cancers, published in two parts in the journal Cancer, developed by the Peritoneal Surface Malignancies Consortium with input from more than 138 specialists in the field. See Part 1: tumors without peritoneal involvement and Part 2: tumors with peritoneal involvement.
This page is reviewed by leading appendiceal cancer researchers.